[Survival benefit from the addition of bevacizumab to first-line radiochemotherapy for the treatment of proneural glioblastoma?]

Strahlenther Onkol. 2016 Jan;192(1):65-6. doi: 10.1007/s00066-015-0922-3.
[Article in German]
No abstract available

Publication types

  • Comment

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antineoplastic Agents, Alkylating / therapeutic use*
  • Bevacizumab / therapeutic use*
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / mortality*
  • Dacarbazine / analogs & derivatives*
  • Female
  • Glioblastoma / drug therapy*
  • Glioblastoma / mortality*
  • Humans
  • Male

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents, Alkylating
  • Bevacizumab
  • Dacarbazine